SG10201908354VA - Riluzole prodrugs and their use - Google Patents
Riluzole prodrugs and their useInfo
- Publication number
- SG10201908354VA SG10201908354VA SG10201908354VA SG10201908354VA SG 10201908354V A SG10201908354V A SG 10201908354VA SG 10201908354V A SG10201908354V A SG 10201908354VA SG 10201908354V A SG10201908354V A SG 10201908354VA
- Authority
- SG
- Singapore
- Prior art keywords
- riluzole
- prodrugs
- release
- cancer
- riluzol
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004181 riluzole Drugs 0.000 title abstract 5
- 239000000651 prodrug Substances 0.000 title abstract 4
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000010224 hepatic metabolism Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001839 systemic circulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4636—Immune checkpoint inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127684P | 2015-03-03 | 2015-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201908354VA true SG10201908354VA (en) | 2019-10-30 |
Family
ID=56848452
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201908354V SG10201908354VA (en) | 2015-03-03 | 2016-02-26 | Riluzole prodrugs and their use |
SG11201706831RA SG11201706831RA (en) | 2015-03-03 | 2016-02-26 | Riluzole prodrugs and their use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706831RA SG11201706831RA (en) | 2015-03-03 | 2016-02-26 | Riluzole prodrugs and their use |
Country Status (25)
Country | Link |
---|---|
US (9) | US10639298B2 (el) |
EP (2) | EP3265448B1 (el) |
JP (2) | JP6700293B2 (el) |
KR (2) | KR102587894B1 (el) |
CN (1) | CN107567438B (el) |
AU (3) | AU2016226463B2 (el) |
BR (1) | BR112017018832B1 (el) |
CA (1) | CA2978158C (el) |
CY (1) | CY1125112T1 (el) |
DK (1) | DK3265448T3 (el) |
EA (1) | EA034759B1 (el) |
ES (1) | ES2905318T3 (el) |
HK (1) | HK1248706A1 (el) |
HR (1) | HRP20220208T1 (el) |
HU (1) | HUE058204T2 (el) |
IL (2) | IL253989B (el) |
LT (1) | LT3265448T (el) |
MX (1) | MX2017011196A (el) |
PH (1) | PH12017501576A1 (el) |
PL (1) | PL3265448T3 (el) |
PT (1) | PT3265448T (el) |
RS (1) | RS62915B1 (el) |
SG (2) | SG10201908354VA (el) |
SI (1) | SI3265448T1 (el) |
WO (2) | WO2016140879A1 (el) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013138753A1 (en) * | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
CA2967662A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual formulation of riluzole |
US20210228549A1 (en) * | 2015-03-03 | 2021-07-29 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
US11911369B2 (en) | 2015-03-03 | 2024-02-27 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
MX2017011196A (es) | 2015-03-03 | 2018-05-22 | Biohaven Pharm Holding Co Ltd | Farmacos precursores de riluzol y sus usos. |
JP2017061430A (ja) * | 2015-09-25 | 2017-03-30 | 芳男 ▲浜▼田 | 新規なプロドラッグ |
EP3458053B1 (en) * | 2016-05-20 | 2021-12-08 | Biohaven Pharmaceutical Holding Company Ltd. | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |
WO2018031707A1 (en) * | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
US20210212999A1 (en) * | 2017-01-18 | 2021-07-15 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
WO2018136918A1 (en) | 2017-01-23 | 2018-07-26 | Cadent Therapeutics, Inc. | Methods for the treatment of tremors by positive modulation of sk channels |
WO2018157820A1 (zh) * | 2017-02-28 | 2018-09-07 | 正大天晴药业集团股份有限公司 | 氮杂环丁烷衍生物 |
CN107021959A (zh) * | 2017-05-02 | 2017-08-08 | 青岛科技大学 | 一类新型吲哚衍生物及其体外抗肿瘤活性 |
SG11202004332XA (en) * | 2017-11-12 | 2020-06-29 | Biohaven Pharm Holding Co Ltd | Use of riluzole prodrugs to treat ataxias |
KR20210034621A (ko) * | 2018-07-22 | 2021-03-30 | 바이오하벤 테라퓨틱스 리미티드 | 알츠하이머병 치료를 위한 릴루졸 전구약물의 용도 |
JP2021534160A (ja) * | 2018-08-16 | 2021-12-09 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | 疾患処置のためのリルゾール口腔内崩壊錠の使用 |
GB201818651D0 (en) * | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
KR20220080133A (ko) * | 2019-10-10 | 2022-06-14 | 바이오하벤 테라퓨틱스 리미티드 | 골수퍼옥시다제 저해제의 전구약물 |
CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
BR112022025901A2 (pt) * | 2020-06-24 | 2023-01-10 | Biohaven Therapeutics Ltd | Composições e métodos para tratar transtorno obsessivo-compulsivo |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
EP4277624A1 (en) * | 2021-01-18 | 2023-11-22 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
WO2022178425A1 (en) * | 2021-02-22 | 2022-08-25 | Yale University | Targeted bifunctional degraders |
KR20240025777A (ko) | 2022-08-19 | 2024-02-27 | 부산대학교 산학협력단 | 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물 |
CN114344297B (zh) * | 2022-03-01 | 2024-05-14 | 暨南大学 | 利鲁唑在治疗少精症中的应用 |
WO2024006678A1 (en) * | 2022-06-26 | 2024-01-04 | Biohaven Therapeutics Ltd. | Methods of treating glioblastoma with prodrugs of riluzole |
CN118085016B (zh) * | 2024-04-24 | 2024-07-30 | 天津卡普希科技有限公司 | 一种d-苯甘氨酰-甘氨酸的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1043319B1 (en) * | 1997-11-05 | 2005-03-16 | Mitsubishi Chemical Corporation | Novel alkylamino derivatives |
JP2005505506A (ja) * | 2001-06-12 | 2005-02-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用な大環状分子 |
EP1680431A1 (en) * | 2003-10-17 | 2006-07-19 | Rigel Pharmaceuticals, Inc. | Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors |
US20070244153A1 (en) * | 2004-07-21 | 2007-10-18 | Mitsui Chemicals, Inc. | Diamine Derivative, Process of Preparation Thereof, and Fungicide Comprising Diamine Derivative as an Active Ingredient |
DK2201963T3 (en) | 2005-04-05 | 2016-02-15 | Univ Yale | Glutamate-modulating agents in the treatment of mental disorders |
FR2885129B1 (fr) * | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
WO2013138753A1 (en) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
US10357497B2 (en) | 2012-06-23 | 2019-07-23 | Biohaven Pharmaceutical Holding Company Limited | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis |
US11911369B2 (en) * | 2015-03-03 | 2024-02-27 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
MX2017011196A (es) * | 2015-03-03 | 2018-05-22 | Biohaven Pharm Holding Co Ltd | Farmacos precursores de riluzol y sus usos. |
US20210228549A1 (en) * | 2015-03-03 | 2021-07-29 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
ES2969792T3 (es) | 2015-11-19 | 2024-05-22 | Biohaven Therapeutics Ltd | Profármacos de amina de compuestos farmacéuticos |
EP3458053B1 (en) * | 2016-05-20 | 2021-12-08 | Biohaven Pharmaceutical Holding Company Ltd. | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |
WO2018031707A1 (en) | 2016-08-10 | 2018-02-15 | Biohaven Pharmaceutical Holding Company Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
SG11202004332XA (en) | 2017-11-12 | 2020-06-29 | Biohaven Pharm Holding Co Ltd | Use of riluzole prodrugs to treat ataxias |
-
2016
- 2016-02-26 MX MX2017011196A patent/MX2017011196A/es unknown
- 2016-02-26 JP JP2017546176A patent/JP6700293B2/ja active Active
- 2016-02-26 ES ES16759303T patent/ES2905318T3/es active Active
- 2016-02-26 SG SG10201908354V patent/SG10201908354VA/en unknown
- 2016-02-26 CN CN201680025374.6A patent/CN107567438B/zh active Active
- 2016-02-26 PT PT167593037T patent/PT3265448T/pt unknown
- 2016-02-26 PL PL16759303T patent/PL3265448T3/pl unknown
- 2016-02-26 WO PCT/US2016/019787 patent/WO2016140879A1/en active Application Filing
- 2016-02-26 CA CA2978158A patent/CA2978158C/en active Active
- 2016-02-26 US US15/549,152 patent/US10639298B2/en active Active
- 2016-02-26 AU AU2016226463A patent/AU2016226463B2/en active Active
- 2016-02-26 KR KR1020177027618A patent/KR102587894B1/ko active IP Right Grant
- 2016-02-26 RS RS20220149A patent/RS62915B1/sr unknown
- 2016-02-26 EP EP16759303.7A patent/EP3265448B1/en active Active
- 2016-02-26 US US15/549,154 patent/US10485791B2/en active Active
- 2016-02-26 SG SG11201706831RA patent/SG11201706831RA/en unknown
- 2016-02-26 KR KR1020237034132A patent/KR20230147746A/ko active Application Filing
- 2016-02-26 EP EP21209037.7A patent/EP4011870A1/en active Pending
- 2016-02-26 HR HRP20220208TT patent/HRP20220208T1/hr unknown
- 2016-02-26 HU HUE16759303A patent/HUE058204T2/hu unknown
- 2016-02-26 WO PCT/US2016/019773 patent/WO2016140878A2/en active Application Filing
- 2016-02-26 LT LTEPPCT/US2016/019787T patent/LT3265448T/lt unknown
- 2016-02-26 DK DK16759303.7T patent/DK3265448T3/da active
- 2016-02-26 EA EA201791951A patent/EA034759B1/ru unknown
- 2016-02-26 SI SI201631457T patent/SI3265448T1/sl unknown
- 2016-02-26 BR BR112017018832-5A patent/BR112017018832B1/pt active IP Right Grant
-
2017
- 2017-08-14 IL IL253989A patent/IL253989B/en active IP Right Grant
- 2017-08-31 PH PH12017501576A patent/PH12017501576A1/en unknown
-
2018
- 2018-07-04 HK HK18108642.5A patent/HK1248706A1/zh unknown
-
2019
- 2019-06-24 US US16/449,948 patent/US10905681B2/en active Active
- 2019-11-20 US US16/689,150 patent/US11052070B2/en active Active
-
2020
- 2020-04-30 JP JP2020080638A patent/JP7012117B2/ja active Active
- 2020-09-15 AU AU2020233650A patent/AU2020233650B2/en active Active
- 2020-10-15 IL IL278080A patent/IL278080B/en unknown
-
2021
- 2021-02-01 US US17/164,654 patent/US12005046B2/en active Active
- 2021-07-05 US US17/367,484 patent/US20230017637A1/en active Pending
-
2022
- 2022-03-24 CY CY20221100236T patent/CY1125112T1/el unknown
- 2022-03-30 AU AU2022202163A patent/AU2022202163B2/en active Active
-
2023
- 2023-07-29 US US18/361,838 patent/US20230381150A1/en active Pending
- 2023-07-29 US US18/361,837 patent/US12005047B2/en active Active
- 2023-07-29 US US18/361,836 patent/US20240091205A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501576A1 (en) | Riluzole prodrugs and their use | |
WO2018140831A3 (en) | Tumor targeting conjugates and methods of use thereof | |
PH12019501959A1 (en) | Therapeutic rna | |
MX2015016277A (es) | Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa. | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
TW201613593A (en) | Molecules for administration to ROS1 mutant cancer cells | |
MX2017007321A (es) | Terapias de combinacion. | |
SA518400552B1 (ar) | مركبات فوسفوراميدات | |
SG10201907684PA (en) | Androgen receptor modulator and uses thereof | |
MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
MY195081A (en) | Pladienolide Pyridine Compounds and Methods of use | |
MD4643C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
IN2014MU00303A (el) | ||
MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MX2016008042A (es) | Derivados de imidazopirazinona. | |
PH12018502360A1 (en) | 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers | |
MX2018005312A (es) | Composiciones y metodos para el tratamiento de la homocistinuria. | |
MX2018005515A (es) | Derivados de 1,4-dicarbonil-piperidilo. | |
MX2016005900A (es) | Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer. | |
MX2017009608A (es) | Compuestos anticancerigenos. | |
MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. |